Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study SuccessSeeking Alpha • 08/30/21
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease CandidateBenzinga • 08/16/21
Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/31/21
Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to DeclineZacks Investment Research • 07/22/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNewsfile Corp • 06/05/21
Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More DataBenzinga • 05/26/21
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental GlomerulosclerosisGlobeNewsWire • 05/25/21
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Earnings Preview: Travere Therapeutics (TVTX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/29/21
Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care ConferenceGlobeNewsWire • 04/27/21
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
Travere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/01/21
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/01/21